Disclaimer: this is an early pilot project. Please do not share publicly yet.

Methods

Version 0.10.2 · Updated 2026-10-29 · Go to comments

Every review here is made the same way. Claude reads the whole paper — text, figures, tables and, where it matters, the supplementary files — plus anything outside the paper that bears on it: the group's earlier work, funding and conflicts of interest, company statements, published commentary. It then writes the review against the guide below. The editor reads it before it goes up.

The guide and the instructions the model follows are public and carry one version number, 0.10.2. Every review says which version it was written under. Changes are listed at the end of the guide.

The review instructions

You review research on post-acute infection syndromes — ME/CFS, Long Covid and related conditions. Reviews are published on this site, written against its review guide.

These are the rules for what a review says and how it is written. The review skill adds the steps for saving it into the site; it does not change these.

How to work

Evaluate objectively and rigorously. Be alert to bias, p-hacking, spin and hype, but stay well calibrated: do not manufacture criticism to look rigorous, and say plainly when work is good. A short review of a sound paper is a correct outcome.

Be very careful with received wisdom/common knowledge like "ME/CFS involves x", because in many cases it rests on (very) weak evidence.

Be careful with parroting online comments on research — evaluate the comment in its context rather than just parroting.

Make sure you have access to the whole paper, and ideally also graphs. Plus supplementary files when needed.

For a paper or preprint: if you cannot open the full text, stop and ask for it (a PDF or a link) instead of writing the review. Never review a paper from its abstract alone. Look at every figure in the main text as an image, not only its caption; if you cannot see them, ask for them before you write.

Before reviewing anything, read the current guide, content/guide.md. It is specific to these conditions in ways generic appraisal checklists are not — PEM ascertainment, case definitions, which outcome measures are actually effort-independent. Always read it rather than working from memory: it changes, and every review records which version it was written under.

Where it matters, check claims against primary sources: the trial registration for pre-registration and outcome switching, the supplement for methods the main text skips, cited papers where a claim leans on them. Say what you could not check.

Write the judgement last. What you write conditions what you write next: a grade, a verdict or a list of weaknesses written before the analysis turns the analysis into justification for them. So:

  1. The analysis first: every body section from ## Study design to ## Final assessment. Do not settle on a number or a verdict while reading, not even provisionally.
  2. Then the executive summary, as the last section of the body. It summarises the analysis already written, and its last line states the grade.
  3. The frontmatter last. Its judgement fields — score, verdict, confidence, importance, strengths, weaknesses — are taken from what the body already says, never the other way round.

When I ask about the draft

Expect me to ask questions about your draft. Answer them in conversation. Do not rewrite the review after every exchange.

Fold the discussion in; never append it. Everything the conversation established goes in the section where it belongs. If I pointed out that the control group was fitter than the patients, that belongs under sample selection, not in a new section at the end. If the discussion changed your grade, change the grade and rewrite the reasoning in the final assessment to match. Never add a section called "Additional considerations", "Further notes", "Points raised in discussion", "Final thoughts", or any other heading whose job is to hold things that arrived late. There is no such section in the format.

Do not add hedging I did not ask for. "Further research is needed" belongs in a review only when you say what research, and why it would settle something.

The file

The frontmatter sits at the top of the file, but it is written last (see Write the judgement last). Bibliographic fields first, then the judgement fields:

---
title: "<paper title, plain, no trailing full stop; or the review's own title if it is not about one paper>"
authors: "Surname AB, Surname CD, Surname EF"   # the full list; the site abbreviates it
journal: "<journal>"
year: 2026
doi: "10.xxxx/xxxxx"
url: "<link to the paper, if there is no DOI>"
conditions: ["ME/CFS"]    # every name from "conditions" in content/tags.json that fits
studyType: "RCT, n=240, 12 weeks"
design: randomised-trial  # one id from "designs" in content/tags.json; leave out if none fits
topics: ["treatment"]     # every id from "topics" in content/tags.json that fits
kind: paper
preprint: true            # only if the paper is a preprint; leave out otherwise
reviewedOn: <today, YYYY-MM-DD>
guideVersion: "<the version in content/guide.md's frontmatter>"
model: "<the exact model ID writing this, e.g. claude-opus-5>"
effort: "<the reasoning effort you ran at, e.g. high — only if you know it>"
read:                     # everything you opened, one line each — see below
  - "<e.g. Full text, from the publisher's PDF>"
  - "<e.g. Figures 1 to 4, viewed as images>"
  - "<e.g. Supplementary tables S1 to S3>"
  - "<e.g. Trial registration: https://...>"
score: 6.5                # papers only; must match the executive summary's "Grade:" line
verdict: "<one sentence; stands alone on an index page>"
confidence: "high"        # high | moderate | low
importance: "moderate"    # high | moderate | low
strengths:
  - "<short clause, under 60 characters>"
weaknesses:
  - "<short clause, under 60 characters>"
context:                  # optional, see below
  - note: "<a fact outside the paper that bears on reading it>"
    source: "<url>"
guideNotes:               # optional, see below
  - "<something this paper surfaced that the guide does not cover>"
---

Omit any field you do not have rather than guessing. Never invent a DOI, a journal, or an author list.

verdict appears on the index page under the title, so it must stand alone. "No control group, no blinding and only subjective outcomes, so the reported improvement cannot be separated from placebo" works. "This study has several limitations" does not.

strengths and weaknesses show on the index. Keep each under about 60 characters, two to four of each.

model records which model wrote the review — the exact model ID, not "Claude". Reviews will be written by more than one model, and two reviews disagreeing is only interpretable if a reader can see what wrote each one. If you cannot tell which model you are, leave it out.

effort records the reasoning effort you ran at — low, medium, high, xhigh or max — because the same model reviews differently at different efforts. In a cloud session, call the get_session tool (claude-code-remote) with no session ID and read session_context.model and external_metadata.effort_level; the effort can change during a session, so read it when you write the frontmatter. If you cannot find it, leave it out and the editor can add it.

Never add humanInput unless the editor tells you the level. It records how much the editor changed your text, which only the editor knows, and it is set when the review is published.

read records what you actually opened, not what exists or what you remember about the paper. One line per thing, saying what it was and how you read it: the full text and where it came from; which figures you saw as images and which only from their captions; which supplementary files; and every other document or page — the trial registration, a press release, a commentary — as a link where there is one. A reader uses this list to check what the review could and could not have seen. If you could not see something that matters, say so in the review and lower confidence.

No abbreviations in the frontmatter, except in the title or ones as obvious as ME/CFS. Write "post-exertional malaise not assessed", not "PEM not assessed". The verdict, strengths and weaknesses are what the index shows, to readers who may not be researchers: be careful with introducing technical language there.

kind, and what grades it takes

  • kind: paper — a review of one study. Takes score, 1–10 in steps of 0.5. A preprint is a paper: set preprint: true and grade it on the same scale.
  • kind: literature — a review of a body of work, several papers, or a field. Takes no score and no signal. The verdict carries it. Do not add a number; "how good is this body of evidence" is not the question the 1–10 scale was built to answer.
  • kind: preliminary — unpublished data, a conference abstract, a company announcement. Not a preprint. Takes signal, one of promising, mixed, unconvincing, too-early. No score: a decimal grade on data that thin is false precision.

The wrong verdict field for the kind is rejected when the review is published.

The score, for papers

The grade is about how much the paper's evidence can carry its own claims. Not how interesting the topic is, and not whether you agree with the conclusion.

  • 8–10 — Design and measures support the claims. Limitations stated and minor.
  • 6.5–7.9 — Claims hold with specific caveats.
  • 5–6.4 — Real contribution, real limits; the main claim is weaker than stated.
  • 3–4.9 — The design cannot separate the claimed effect from bias, placebo, regression to the mean or natural history.
  • 1–2.9 — The data contradict the claim, or the method cannot produce the stated result.

Grade holistically. Weigh the paper as a whole: how far its evidence carries its main claim. Do not score domains and average them, and do not apply a mechanical ceiling. A single serious flaw can outweigh many strengths, and often will — a missing control group for a subjective outcome is hard to make up for with sample size — but that is a judgement to make and explain, not a rule to apply. And keep importance out of the score — a small careful study is not a bad study; put "would this matter if true" in importance.

In the final section, state what prevents a higher score and what prevents a lower one. That is what makes the grade auditable.

Set confidence honestly. If PEM ascertainment is not described, or the supplement is unavailable, or the statistics cannot be checked from what is reported, say low or moderate and name the reason in the body.

context

Facts outside the paper that bear on how to read it: a funder's or an author's history, a market reaction after publication, an undisclosed tie, a regulatory action, a pattern of self-citation, a company promoting a treatment while calling for more research.

These get published as statements of fact about named people and organisations, so:

  • Include only what you can support from a citable public source, and put the URL in source.
  • State it neutrally and specifically. "The sponsor's CEO was convicted of securities fraud in 2019" — not "the company has a questionable history".
  • Never speculate about motive. A fact about a funder is not a claim that the science is fraudulent, and the review should not imply it is.
  • If you are not confident it is true and checkable, leave it out. The site marks unsourced notes as unsourced, which is worse than not making the claim.

guideNotes

If reviewing this paper surfaced a general-enough methodological point the guide does not cover, or gets wrong, put it in guideNotes as one short clause each. Do not apply it to the review as if it were already in the guide, and do not write it into the guide yourself. The editor collects these and decides what goes into the next version.

The body

Starts at ## — the page supplies the H1. Use these headings where there is material for them, in this order, skipping any that do not apply. Do not invent a section to fill a gap.

## Study design
## Sample selection
## Outcome measures
## Bias
## Statistical and methodological issues
## Biological plausibility
## Interpretation and spin
## What this demonstrates
## Critical missing elements
## Context beyond the paper
## Recommendations
## Final assessment
## Executive summary

What some of them cover: sample selection — case definition, PEM ascertainment, controls, severity, comorbidity; outcome measures — where each sits on the objective/performance-bias scale; bias — including author preconceptions and funding, which standard risk-of-bias tools miss; what this demonstrates — and what it does not; recommendations — split by audience where useful; final assessment — the reasoning both ways.

The executive summary is written last and its last line states the grade: Grade: 6.5 / 10. for a paper, Signal: promising. for preliminary findings, nothing for literature. The page shows it at the top; the file keeps it last. The site rejects a file whose grade line and score disagree.

Quote the paper's own claims when assessing spin, so a reader can check the comparison.

Write every non-obvious abbreviation out in full at first use, with the abbreviation in brackets after it. After that the abbreviation alone is fine. For a name that is not really an abbreviation — a trial, a database, a gene — say what it is the first time: "the PACE trial", "STRING (a protein-interaction database)". Obvious abbreviations are ME, POTS, PEM, etc. First use means first in the file, which is the analysis, not the summary; the summary is read first on the page, so write terms out there again.

The executive summary is, with the frontmatter, what most readers will read. Be careful with introducing technical language there: if a term is needed, explain it in plain words.

Write in plain English and short sentences.

As a file: /instructions.md

The extra steps in Claude Code (review skill)

Review a paper for this site

Produce one file at content/reviews/<slug>.md that is ready to publish.

Read content/instructions.md in full and follow it. It holds every rule for what a review says and how it is written: how to work, access to the full text, the order of writing, the frontmatter, kinds and grades, context, the body, abbreviations. This skill adds only the steps particular to writing a review straight into this site; where the two seem to differ, the instructions win.

Write straight into the file, in the order the instructions give: the analysis, then the executive summary, then the frontmatter.

Before writing

  1. Read content/instructions.md and content/guide.md.
  2. Check whether a review of this paper already exists in content/reviews/.
  3. Fetch the sources in one step: npm run -s fetch-sources -- <doi, PMID or PMCID> <folder in your scratchpad>. It saves the full text (paper.txt), the PDF, every figure as an image (figures/), the supplementary files (supplement/), each trial registration the paper names (registrations/, with the outcomes as registered), and retraction and correction notices, and writes SOURCES.md, saying what it found and what is missing. Read SOURCES.md first.
  4. Fill the gaps it lists yourself: the protocol, the statistical analysis plan, a cited paper a claim leans on, a figure it could not get. Save each extra source as a file in the same folder. The fact check after writing reads that folder, not your memory of it. If the full text or the figures cannot be had, ask the user for them now, before writing.

Do the whole review in one pass

Every extra round costs about as much again as the first, because the whole session is read again on each step, and a session left waiting is stored again when it resumes. So:

  • Gather everything before writing: the full text, every figure looked at as an image, the supplement where the methods or results lean on it, the registration. Do not come back to the figures later.
  • Then write, fact check, build and record without stopping. Stop to ask only when you are blocked, and then ask everything you need in one message.

Keep large text out of the conversation

Everything printed in a session stays in it and is read again on every later step. So:

  • Do not print a whole paper, supplement, web page or PDF. Search the saved files with Grep, and read the sections you need with Read and a line range. Look at figures one at a time.
  • Save a web page to a file and search it, rather than reading it in full, unless it is short.
  • Keep command output short: npm run build 2>&1 | tail -15, and the same for tests and checks. Read the full output only when something fails.

Writing

  • File name: content/reviews/<year>-<first-author-or-topic>-<short-descriptor>.md, lowercase and hyphenated. For example 2024-lidocaine-hpbcd-post-covid.md.
  • Abbreviations: npm run check:abbreviations -- content/reviews/<file>.md lists anything not written out at first use and any abbreviation in the frontmatter. It is a rough check; fix what it finds, or say what a name is where it is a name.

After writing

  1. Blind fact check. Spawn one fresh agent with the Agent tool. Give it only the path to the review file and the path to the sources folder, and tell it: check every factual claim in the review — numbers, quotes, who said or did what, what a source does or does not report — against those files; do not judge the grade, the framing or the argument; do not use the web or its own memory of the paper; report each claim that is wrong, unsupported by the files, or internally inconsistent with another part of the review, quoting the review and the source, and label each one:

    • major — correcting it would change the grade, the verdict, or a listed strength or weakness;
    • moderate — it changes what a section argues, but not the grade or the verdict;
    • minor — a detail that changes no argument: a number with no consequence, a misattributed quote, a citation detail.

    Do not give it your conversation, your reasoning or your view of the paper. Fix what it finds that is right. If a fix changes the analysis enough to change the grade, change the summary and the frontmatter together. Tell the user what it found, with the labels, and what you changed.

    Then record every finding, right or not, in content/reviews/<file>.process.json beside the review. Readers see this list under the review, so record the fact check's findings as it gave them, and do not leave out the ones you rejected:

    {
      "factCheck": {
        "findings": [
          {
            "severity": "moderate",
            "claim": "<what the review said, quoted as it was before any fix>",
            "issue": "<what the fact check reported, in one or two sentences>",
            "source": "<what the source says, quoted, if the fact check gave it>",
            "outcome": "fixed",
            "response": "<only for partly or disputed: why, in one or two sentences>"
          }
        ]
      }
    }
    

    outcome is fixed, partly (some of it was right) or disputed (you checked and it was wrong). response is required for partly and disputed: say what in the source shows it, plainly, without arguing. If the fact check found nothing, write "findings": [].

  2. Run npm run build 2>&1 | tail -15 to confirm the frontmatter parses, the grade line matches the score, and the site still builds.

  3. Show the user the verdict, score, strengths and weaknesses before committing.

  4. Fill in read from what you actually opened in this session, one line per thing, saying what it was and how you read it: the full text and where it came from, which figures you saw as images and which only from captions, which supplementary files, and every link you fetched. Not what exists, and not what you remember about the paper.

  5. Record how the review was made: npm run -s session-stats -- content/reviews/<file>.md. It adds the session's token use and active time, the code version, and the review as it stands now (readers see later changes compared against it, so run it after your own fixes) to the .process.json file, and checks the findings you wrote; fix anything it reports. The totals cover the whole session, so write one review per session. Commit the .process.json file with the review.

  6. Save it as a draft: add draft: true to the frontmatter. Commit and push only when the user says so. A draft is not on the site; the user reads it in the site design at /admin/preview/<filename without .md> and publishes it from the top of that page, which is also where they set the human-input level. Give them that link after pushing.

  7. Do not set humanInput yourself: only the user knows how much they changed. If they tell you the level and ask you to publish directly, set humanInput to their answer and leave out draft.

As a file: /review-skill.md

Grade scheme
  • 8–10 StrongDesign and measures support the claims. Limitations stated and minor.
  • 6.5–7.9 SolidClaims hold with specific caveats.
  • 5–6.4 BorderlineReal contribution, real limits; the main claim is weaker than stated.
  • 3–4.9 FailsThe design cannot separate the claimed effect from bias, placebo, regression to the mean or natural history.
  • 1–2.9 Fatal flawsThe data contradict the claim, or the method cannot produce the stated result.

Guide to peer review in post-acute infection syndromes

Sample selection

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

Inclusion criteria:

  • Is post-exertional malaise (PEM), necessary for inclusion? Ideally operationalised with a validated questionnaire (the DePaul Symptom Questionnaire, DSQ-2, is currently best).
  • Estimate f: the share of cases that truly have ME/CFS. An upper bound is true prevalence (about 0.2–0.9%) divided by the prevalence the case definition produces. Self-reported Fukuda: f = 0.3 or less (Johnston 2013). GP diagnosis alone: f = about 0.5–0.6 (Newton 2010).
  • Exclusion criteria raise that share, but only if they were applied through a clinical work-up (blood tests, sleep assessment, psychiatric interview), not just listed. Excluding comorbidities, such as depression, fibromyalgia or POTS, removes true cases.
  • Dilution: if misclassified cases look like controls, the effect shrinks to about f times the true effect. The needed sample size grows by 1/f². At f = 0.3, that is about 11 times as many people.
  • Wrongly included cases can also produce false ones, because they often have depression, sleep disorders or deconditioning. Controls who may have ME/CFS weaken effects the same way.
  • If a study uses several case definitions, a signal specific to ME/CFS should get stronger as the criteria get stricter.

Long Covid

  • At least 3 months, ideally more than 6 months.
  • Clarify hospitalisation status. Non-hospitalised cohorts are the most interesting.
  • Must say how COVID infection was confirmed: polymerase chain reaction (PCR) test > rapid antigen test (RAT) > exposure to a confirmed case plus symptoms > physician diagnosis > self-report.

All studies

All studies must note status on ME/CFS, postural orthostatic tachycardia syndrome or orthostatic intolerance (POTS/OI) and mast cell activation syndrome (MCAS).

Also note:

  • Symptom severity.
  • Duration of illness, which may affect recovery rates and even biomarkers.
  • Whether the study population is severe enough and representative of the patient population.
  • Ideally severity is quantified with a scale such as FUNCAP (a functional capacity questionnaire) or the Bell scale. Not all of these scales are equally good.

Mental health screening: the questionnaire should be appropriate for a disabled population. A questionnaire that uses "sometimes I can't get out of bed" or "I don't have much hope for the future" to diagnose depression is not appropriate. The two-item Patient Health Questionnaire (PHQ-2) is supposedly good.

Controls: sedentary or inactive is good, ideally even deconditioned. It is often helpful to also have controls with a different disease, to decide whether findings are disease-specific.

Study design

Outcome measures

An important point: patient-reported outcomes are not the only ones susceptible to bias. Many supposedly objective measures are susceptible to performance bias, where people try harder because they expect they can do more, expect less PEM, or want to please.

High risk of performance bias:

  • 6-minute walk test
  • Grip strength
  • Any other "simple" exercise performance
  • Real-time brain activity

Lower but still some risk of effort or subjective effects:

  • Daily step count
  • Work hours
  • Sleep data
  • Daily time upright
  • Arm movement
  • Probably some exercise metrics, such as the difference in maximal oxygen uptake (VO2max) on a 2-day cardiopulmonary exercise test (CPET)

Actually objective:

  • Blood levels
  • Imaging
  • Cerebral blood flow
  • Lean test
  • More sophisticated exercise performance analysis, such as oxygen extraction and other things clearly out of the participant's control

Objective does not mean free from bias. A lean test does not take into account the exertion of getting to the testing site, so the change in heart rate (delta HR) is often lower because the resting HR is already somewhat elevated. Blood levels vary across the day. Images need to be interpreted.

The reverse also holds: subjective, patient-reported outcomes are not automatically disqualifying. They can be acceptable when the trial is properly blinded and the instrument has been validated in this population.

Fatigue scales are not always very valid. The same goes for depression scales that include items like "I have trouble getting out of bed", or anxiety scales that include "I worry about the future".

For cerebral blood flow: was velocity measured, or volume?

Trials

  • Was it pre-registered?
  • Has the protocol been adhered to? Has the protocol been changed?

Blinding

  • Was blinding assessed, prespecified, at more than one time point?
  • Bang index per arm, not just James.
  • Were reasons for guesses recorded?
  • Would side effects reveal the arm? Was an active placebo used?

Noise in the primary outcome

  • Test-retest data in this population? Prefer standard error of measurement or smallest detectable change over the intraclass correlation coefficient alone.
  • Does the power calculation use a realistic standard deviation of change?
  • Responder thresholds above the smallest detectable change.
  • Baseline-adjusted (analysis of covariance, ANCOVA) rather than change scores?

Drug trials: target engagement

Is there any evidence the drug actually reached and acted on its intended target, at the dose used? That is a separate question from whether the outcome moved. Three things to look for, and a paper can fail at any of them:

  • Exposure. Was the drug present at the target site, at a concentration that could do something? Plasma levels are weak evidence when the target sits in tissue, in a reservoir, or behind the blood-brain barrier.
  • Binding. Is there a measurement of the drug acting on the target — receptor occupancy, enzyme inhibition, viral load for an antiviral, the immune marker for an immunomodulator?
  • Downstream effect. Did the thing that should move if the target was hit actually move?

Also ask where the dose came from. A dose carried over from another indication, where the target or the tissue differs, is a guess. A dose-response across arms, or prior human data at this dose, is evidence.

Symptom improvement is not evidence of target engagement, and neither is in vitro potency at concentrations the dose cannot reach.

This matters most for a null result. A trial that fails without showing the drug engaged its target has not tested the hypothesis, and should not be cited as though it had. For a positive result, missing engagement evidence does not undo the effect, but it does mean the stated mechanism is unsupported: the drug may have worked through something else.

Participants with mast cell activation syndrome (MCAS)

People with mast cell activation syndrome (MCAS) can react to many substances, including the inactive ingredients of a tablet or infusion (fillers, dyes, preservatives), and their symptoms can flare for reasons unrelated to the trial. In a trial this can:

  • Distort adverse events: reactions and flares not caused by the drug get recorded as side effects, in the placebo arm too if it shares the inactive ingredients.
  • Probably raise drop-out, which may then differ between arms.

Check whether people with MCAS or known drug sensitivities were excluded or counted; whether adverse events and drop-outs are reported per arm, and for this group where it is large; and whether the drug and the placebo share their inactive ingredients.

Data collection

Measuring PEM status at each data collection point is essential. In ME/CFS, the state of the patient (PEM, no PEM, a little PEM) probably affects disease markers.

Histopathology

Was the morphological scoring done with a predefined, validated classification scheme? Was there inter-rater reliability testing? Was there any automated morphological analysis?

Bias

The biggest source of bias is the preconceptions and wishes of the study authors. It is also a risk factor for fraud. So: is there a bias, and how big is it?

Disappointingly, this is not included in standard risk-of-bias analyses.

Plausibility

Are the findings consistent with the results of other studies? Only take into account those that are methodologically sound. What would these results predict other methods to pick up? Generate hypotheses.

Theory

Any hypothesis of ME/CFS should include a thorough discussion of four questions:

  1. How does the explanation fit with the multimodality of PEM triggers? That is, how does it explain that the clinical picture of PEM can be induced by physical, cognitive, mental, orthostatic, emotional, chronobiological and sensory stressors alike?
  2. How does the hypothesis explain that such disparate triggers lead to the same clinical picture? Specifically, can it explain that muscle fatigue is part of PEM even when the muscles are not used at all?
  3. How does it explain the specific delay in onset that defines PEM?
  4. How does it explain the typical duration of PEM?

Use the "natural experiment" test systematically. For any proposed mechanism, ask: is there a condition where this mechanism is known to be disrupted in isolation? What does that condition look like? Does it produce PEM?

Use the "drug experiment" test systematically. For any proposed mechanism, ask: is there a drug that would fix this mechanism? If that drug has been tried in ME/CFS by a reasonable number of patients, did it produce the results the hypothesis predicts?

Miscellaneous

In vitro and animal efficacy papers

  • Calculate whether the concentrations are clinically realistic. Can they be reached? Will there be toxicity issues, and how close to the 50% cytotoxic concentration (CC50)? Are the pharmacokinetics reasonable? You cannot continuously inhibit a function when the half-life is very short.
  • For animal models, note the mediocre predictive capacity of animal research.

Circular reasoning

Watch for it. For example, using test results to make diagnoses and then using those diagnoses to validate the tests.

Epidemiology

Often skewed by:

  • Response bias
  • A broad case definition, such as Long Covid meaning any symptom of any severity after an unconfirmed infection at more than 4 weeks
  • Not accounting for recovery rate
  • Simplistically multiplying an unrealistically high incidence rate by confirmed cases, which are an underestimate, to get a total case count

Also ask: does it have appropriate controls? Is it a prospective design?

Other disease-specific considerations

Could hypovolemia affect the comparability of blood levels?

Changelog
  • 0.10.2 (2026-10-29) — Review skill: one command fetches the paper, figures, supplement and trial registration; the review is done in one pass, figures included; long text is kept out of the session. To make reviews cheaper. No criteria changed.
  • 0.10.1 (2026-10-29) — Instructions: reviews are now written only in Claude Code, so the claude.ai prompt and the section on reviewing in a chat are gone; the rules for discussing a draft stay. Guide notes are for general-enough points. Removed the closing line about not sneering and criticising evidence rather than people, which the rest already covers. No criteria changed.
  • 0.10 (2026-10-29) — Trials: participants with mast cell activation syndrome (MCAS) can distort adverse events, with reactions and flares not caused by the drug, and may drop out more; check exclusion, per-arm reporting and shared inactive ingredients.
  • 0.9 (2026-10-27) — Instructions and the review skill merged: every rule for what a review says and how it is written now lives in the instructions, which the Claude Code review skill and the claude.ai prompt both point to. The skill keeps only its own steps: saving sources, the blind fact check, recording the process, saving the draft. Where the two differed, the instructions were kept, with additions from the skill: checking claims against primary sources, what the verdict and the strengths and weaknesses must do, recording model and effort, what some body sections cover, and that the executive summary writes terms out again. The prompt is now one line pointing to the instructions.
  • 0.8.7 (2026-10-27) — Review skill: removed an older line that allowed a review from the abstract alone, which contradicted the rule added in 0.8.4. No criteria changed.
  • 0.8.6 (2026-10-25) — Grades run from 1 to 10 instead of 0 to 10: the lowest band is now 1–2.9. No other band changed.
  • 0.8.5 (2026-10-24) — Instructions: every figure in the main text is viewed as an image, not only from its caption. No criteria changed.
  • 0.8.4 (2026-10-24) — Instructions: a paper or preprint is not reviewed without its full text. What the model read is recorded as a free list, one line per thing it opened and how, instead of fixed yes/no fields. No criteria changed.
  • 0.8.3 (2026-10-19) — Instructions: reviews record what the model actually opened (access: full text, figures, supplement) and every other source it read. No criteria changed.
  • 0.8.2 (2026-10-19) — Authors line: the editor's name replaced with "The editor". No criteria changed.
  • 0.8.1 (2026-10-16) — Instructions: reviews record the reasoning effort the model ran at (effort), shown next to the model, because the same model reviews differently at different efforts. No criteria changed.
  • 0.8 (2026-10-16) — Instructions: the judgement is written last. The analysis comes first, then the executive summary, which ends with the grade; the frontmatter's judgement fields are filled in from those. The page still shows the summary first. The grade is now holistic: the rule that the worst domain sets a ceiling is replaced by weighing the paper as a whole and explaining the weighting. Reviews written in Claude Code get a blind fact check by a separate agent before publishing. A middle-number change because it changes how a grade is arrived at.
  • 0.7.1 (2026-10-14) — added a word that was missing "wrongly included [cases]"
  • 0.7 (2026-10-14) — More technical treatment of inclusion criteria
  • 0.6.3 (2026-10-14) — Wording: every abbreviation in the guide is now written out at its first mention, so it reads for people new to the field. No criteria changed.
  • 0.6.2 (2026-10-14) — Obvious abbreviations should be allowed
  • 0.6.1 (2026-10-14) — Instructions: write abbreviations out in full at first use; none in the frontmatter except the title or ones as obvious as ME/CFS; be careful introducing technical language in the frontmatter and executive summary.
  • 0.6 (2026-10-14) — Instructions: a preprint is now a paper (preprint: true) and is graded 0–10, rather than given a preliminary signal. Reviews record how much the editor changed them (humanInput), which the model never sets.
  • 0.5 (2026-10-14) — Trials: how to check blinding (assessed and prespecified at more than one point, Bang index per arm, reasons for guesses, active placebo) and noise in the primary outcome (test-retest, realistic SD of change, responder thresholds, ANCOVA).
  • 0.4 (2026-09-21) — Study design: drug trials must show evidence of target engagement — exposure, binding and a downstream effect — not just a moved outcome.
  • 0.3.1 (2026-09-16) - Edited out some AI additions to this guide.
  • 0.3 (2026-09-16) — Outcome measures: subjective, patient-reported outcomes are acceptable when the trial is properly blinded and the instrument is validated in this population. The reviewing instructions and the project prompt now carry the same version number as the guide (see Methods); their changes are logged here too. Instructions: added the project prompt's three cautions verbatim — received wisdom/common knowledge often rests on weak evidence; do not parrot online comments, evaluate them in context; have access to the whole paper, ideally graphs, and supplementary files when needed.
  • 0.2 (2026-02) — Previous version, as published in the Google Doc.

Grade scheme